Analysis

Molecular Biometrics: $1.68 Stock Flashes 8,700% Upside Potential

By stockpickr AI | April 12, 2026 | 10 min read

MBAI logo

Investment Summary

Molecular Biometrics Inc. is a developmental-stage company focused on medical diagnostics. Trading on OTC Pink, it carries high volatility and speculative risk.

Investment Recommendation

Buy

Fair Value: $148.97

Current Price: $1.68

Upside/Downside: +8767.5%

No recommendation provided

Key Metrics

  • Market Cap: $2.08M
  • P/E Ratio: N/A
  • Dividend Yield: 0.00%
  • Analyst Target Price: $0.00

Strengths

  • Highly speculative, low market cap offers potential for massive percentage gains on product milestones.
  • Development focus on proprietary medical diagnostic technology (if successful).
  • Current trading below $0.01, which may attract short-term volatility traders.

Risk Factors

  • Extremely illiquid stock trading on the OTC Pink market, indicating very high risk and low institutional interest.
  • Company appears to be in the early development or dormant stage with limited recent financial reporting.
  • Lack of established revenue streams or commercial products makes valuation purely speculative.

Latest News

MBAI Form 10-K Annual Report

Filing of the 2023 Annual Report detailing the company's financial position and operations as of year-end.

Source: SEC EDGAR | Sentiment: Neutral

MBAI Price and Volume Data Update

Recent trading activity showing minimal volume and price hovering near the zero mark, typical of inactive OTC stocks.

Source: OTC Markets | Sentiment: Slightly Negative

MBAI Form 10-Q Quarterly Report

Filing of the Quarterly Report for the period ending April 30, 2023, showing minimal business activity.

Source: SEC EDGAR | Sentiment: Neutral